Vit C-treated CD8⁺iTregs alleviate aGVHD. (A-C) B6→BALB/c: lethally irradiated BALB/c mice were adoptively transferred with 1 × 10⁶ CD8⁺ iTregs and 5 × 10⁶ WT TCD-BM cells. Three days later, 0.7 × 10⁶ CD25-depleted T cells were injected IV to induce aGVHD. Recipients were monitored until day 80 for survival rate (A), body weight loss (B), and GVHD clinical signs (C) (n = 10 per group). (D-F) B6→BDF1: lethally irradiated BDF1 mice were infused with 2 × 10⁶ CD8⁺ iTregs and 5 × 10⁶ WT TCD-BM cells. Three days later, 3 × 10⁶ CD25-depleted T cells were injected IV to induce aGVHD. Recipients were monitored until day 80 for survival rate (D), body weight loss (E), and GVHD clinical signs (F) (n = 8-10 per group). Data are combined from 2 independent experiments. *P ≤ .05, **P ≤ .01, ***P ≤ .001, Student t test or log-rank (Mantel-Cox) test.